Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off

INTERPACE BIOSCIENCES, INC.

2026-Q1 EPS reported $0.03 revenue$9,032,000

Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).
Thyroid revenue +14% YoY in Q4, +21% for FY; thyroid volume +11% Q4, +13% FY.
Debt fully paid off in Q4 2025; cash availability up $4.3M YoY.
Adjusted EBITDA Q4 $1.7M, FY $5.4M; company reiterates ~16% thyroid revenue growth guidance for 2026.
Business metrics improved: avg revenue/test +5%, DSO -19%, turnaround time -20%, accounts +9%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTERPACE BIOSCIENCES, INC. reported fourth quarter and fiscal year ended December 31, 2025 results: revenue $9.2 million and $38.7 million, respectively, net income $22.8 million and $25.0 million, respectively.

Period: fourth quarter and fiscal year ended December 31, 2025
Revenue: $9.2 million and $38.7 million, respectively
Net income: $22.8 million and $25.0 million, respectively
Result: reported results

Exact text from the filing

stated in such filing. --- EX-99.1 (EX-99.1) --- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results ● Q4 and FY Revenue of $9.2 million and $38.7 million ● Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) ●

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-014654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.